Trial
NCT05445609
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Phase IISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
National Cancer Institute (NCI); Prostate Cancer Foundation
Condition
Metastatic Prostate Adenocarcinoma
Intervention
VLP-encapsulated TLR9 Agonist CMP-001,
Why stopped
Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored studies with vidutolimod are being paused until further notice
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-19